The latest price target for Summit Therapeutics (NASDAQ:SMMT) was reported by JMP Securities on April 28, 2025. The analyst firm set a price target for $40.00 expecting SMMT to rise to within 12 months (a possible 64.95% upside). 32 analyst firms have reported ratings in the last year.

The latest analyst rating for Summit Therapeutics (NASDAQ:SMMT) was provided by JMP Securities, and Summit Therapeutics reiterated their market outperform rating.

The last upgrade for Summit Therapeutics Inc happened on March 26, 2025 when Citigroup raised their price target to $35. Citigroup previously had a neutral for Summit Therapeutics Inc.

The last downgrade for Summit Therapeutics Inc happened on September 27, 2024 when Citigroup changed their price target from $19 to $23 for Summit Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Summit Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Summit Therapeutics was filed on April 28, 2025 so you should expect the next rating to be made available sometime around April 28, 2026.

While ratings are subjective and will change, the latest Summit Therapeutics (SMMT) rating was a reiterated with a price target of $40.00 to $40.00. The current price Summit Therapeutics (SMMT) is trading at is $24.25, which is out of the analyst’s predicted range.